Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-09-25
2007-09-25
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C435S975000, C435S007100, C530S300000, C530S324000, C530S327000, C530S326000
Reexamination Certificate
active
09500904
ABSTRACT:
Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease. Cells infected with latent virus may also encourage autoimmunity. Based on the understanding that reactivation or latency are important to produce or sustain autoimmunity, then therapies directed against Epstein-Barr virus will also be effective therapies for the autoimmune manifestations of disease for which Epstein-Barr virus is responsible.
REFERENCES:
patent: 4554101 (1985-11-01), Hopp
patent: 4654419 (1987-03-01), Vaughan
patent: 4707358 (1987-11-01), Kieff
patent: 4784942 (1988-11-01), Harley
patent: 4865970 (1989-09-01), Brot et al.
patent: 5312752 (1994-05-01), Woltz et al.
patent: 5354691 (1994-10-01), Van Eden et al.
patent: 5637454 (1997-06-01), Harley
patent: 5679774 (1997-10-01), Wolf
patent: 5723283 (1998-03-01), Classen
patent: 5726286 (1998-03-01), Alderson
patent: 5874531 (1999-02-01), Strominger et al.
patent: 5965353 (1999-10-01), Middeldorp
patent: 0 113 431 (1984-07-01), None
patent: 0 313 156 (1989-04-01), None
patent: WO86/01210 (1986-02-01), None
patent: WO 86/01210 (1986-02-01), None
patent: WO88/09932 (1988-06-01), None
patent: WO 88/09932 (1988-06-01), None
patent: WO91/11718 (1991-08-01), None
patent: WO 91/11718 (1991-08-01), None
patent: WO 91/17171 (1991-11-01), None
patent: WO91/17171 (1991-11-01), None
patent: WO91/18920 (1991-12-01), None
patent: WO93/21223 (1993-10-01), None
patent: WO 94/02445 (1994-02-01), None
patent: WO94/02445 (1994-02-01), None
patent: WO94/02509 (1994-02-01), None
patent: WO 94/02509 (1994-02-01), None
patent: WO 94/06912 (1994-03-01), None
patent: WO94/06912 (1994-03-01), None
patent: WO 94/21669 (1994-09-01), None
patent: WO94/21669 (1994-09-01), None
patent: WO 96/37225 (1996-11-01), None
patent: WO96/37225 (1996-11-01), None
patent: WO98/30586 (1998-07-01), None
White et al. 1994. Medical Virology. Fourth edition. Acedemic Press. pp. 154-155 and 343-347.
Carson. 1992. Genetic factors in the etiology and pathogenesis of autoimmunity. FASEB Journal. vol. 6. No. 10. Abstract only.
Rhodes et al. 1985. Human immune responses to synthetic peptides from the epstein-barr nuclear antigen. The Journal of Immunology. vol. 134. No. 1, pp. 211-216.
Petersen et al. 1990. Altered immune response to glysine-rich sequences of Epstein-Barr nuclear antigen-1 in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis and Rheumatism. vol. 33. No. 7, pp. 993-1000.
Marchini et al. Journal of Autoimmunity. 1994; 7: 179-191.
Alexander, et al., “Anti-Ro/SS-A Antibodies in the Pathophysiology of Congenital Heart Block in Neonatal Lupus Syndrome, and Experimental Model,”Arth. And Rheum.35:176-189 (1992).
Arbuckle, et al., “Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus,”Scand. J. Immunol.50(5):447-55 (1999).
Baraket, et al., “Mapping of epitopes on U1 snRNP polypeptide A with synthetic peptides and autoimmune sera,”Clin. Exp. Immunol.86:71-78 (1991).
Baraket, et al., “Recognition of Synthetic Peptides of Sm-D Autoanigen by Lupus Sera,”Clin. Exp. Immunol.81:256-262 (1990).
Ben-Chetrit, et al., “Isolation and Characterization of a cDNA Encoding the 60-kD Component of the Human SS-A/Ro Ribonucleoprotein Autoantigen,”J. Clin. Inv.83:1284-1292 (1989).
Blank, et al., “Induction of Experimental Anti-phospholipid Syndrome Associated with SLE Following Immunization with Human Monoclonal Pathogenic Anti-DNA Idiotype,”J. Autoimmunity5:495-509 (1992).
Blank, et al., “Induction of SLE-Like Disease in Naive Mice with a Monoclonal anti-DNA Antibody Derived from a Patient with Polymyositis carrying the 16/6 id,”J. Autoimmunity1:683-591 (1988).
Blank, et al., Induction of Systemic Lupus Erythematosus in Naive Mice with T-cell Lines Specific for Human Anti-DNA Antibody SA-1 (16/6 Id+) and for Mouse Tuberculosis Antibody TB/68 (16/6 id+)Clin. Immunol. Immunopathol.60:471-483 (1991).
Blank, et al., “Sex Hormone Involvement in the Induction of Experimental Systemic Lupus Erythematosus by a Pathogenic anti-DNA Idiotype in Naive Mice,”J. Rheumatol.17:311-317 (1990).
Blank, et al., “The Effect of the Immunomodulator Agent AS101 on Interleukin-2 Production in Systemic Lupus Erythematosus (SLE) Induced in Mice by Pathogenic Anti-DNA Antibody,”Clin. Exp. Immunol.79:443-447 (1990).
Bray, et al., “Antibodies Against Epstein-Barr Nuclear Antigen (EBNA) in Multiple Sclerosis CSF, and Two Pentapeptide Sequence Identities Between EBNA and Myelin Basic Protein,”Arch. Neurol.42:1798-1804 (1992).
Bray, et al., “Epstein-Barr Virus Infection and Antibody Synthesis in Patients With Multiple Sclerosis,”Arch. Neurology40:406-408 (1983).
Buyon, “Neonatal Lupus Syndrome,”Curr. Opin. In Rheum.6:523-529 (1994).
Chambers, et al., “Genomic Structure and Amino Acid Sequence domains of the Human La Autoantigen,”J. Biol. Chem.263:18043-18051 (1988).
Chambers, et al., “Isolation and analysis of cDNA Clones Expressing Human Lupus La Antigen,”Proc. Natl. Acad. Sci. USA82:2115-2119 (1985).
Chan, et al., “Ribonucleoprotein SS-B/La belongs to a Protein Family with Consensus Sequences for RNA Binding,”Nucl. Acids Res.17:2233-2244 (1989).
Cohen, “The Self, the World and Autoimmunity—Autoimmunity—In Which the Immune System Recognizes and ATtaks the Self's Own Tissues—Is Not as Simple as it Seemed. Self-recognition Appears to be at the Heart of Health as Well as of Certain Diseases,”Scientific American258:52-60 (1988).
Craft, et al., “Murine and Drosophila B Proteins of SM snRNPS,”Mol. Biol. Rep.15:159 (1991).
Crone, et al., “Viral Transcription is Necessary and Sufficient for Vesicular Stomatis Virus to Inhibit Maturation of Small Nuclear Ribonucleoproteins,”Journal of Virology63(10):4172-4180 (1989).
Dalldorf, et al., “The Lymphomas of Brazilian Children,”J. Am. Med. Assn.208:1365-8 (1969).
Deacon, et al., “Detection of Epstein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Possible Relationship with Sjogren's Syndrome,”J. Pathol.163:351-360 (1991).
Deacon, et al., “Frequency of EBV DNA Detection in Sjogren's Syndrome,”Am J. Med.92:453-454 (1992).
Depolo, et al., “Continuing Coevolution of Virus and Defective Interfering Particles and of Viral Genome Sequences During Undiluted Passages: Virus Mutants Exhibiting Nearly Complete Resistance to Formerly Dominant Defective Interfering Particles,”J. of Virology61:454-464 (1987).
Deutscher, et al., “Molecular Analysis of the 60-kDa Human Ro Ribonucleoprotein,”Proc. Natl. Acad. Sci. USA85:9479-83 (1988).
Dyrberg & Oldstone, “Peptides as Probes to Study Molecular Mimicry and Virus-Induced Autoimmunity,”Current Topics in Microbiology and Immunology130:25-37 (1986).
Elkon, et al., “Epitope Mapping of Recombinant HeLa SmB and B' Peptides Obtained by the Polymerase Chain Reaction,
Harley John B.
James Judith A.
Kaufman Kenneth M.
Campell Bruce R.
Fulbright & Jaworski LLP
Li Bao Qun
Oklahoma Medical Research Foundation
The Board of Regents, The University of Oklahoma
LandOfFree
Diagnostics and therapy of Epstein-Barr virus in autoimmune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostics and therapy of Epstein-Barr virus in autoimmune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostics and therapy of Epstein-Barr virus in autoimmune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3727663